• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    11/14/24 4:05:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email
    SC 13G/A 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    Adicet Bio, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    007002108

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware, USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    1

    NAME OF REPORTING PERSONS

     

    Commodore Capital Master LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    Item 1. (a) Name of Issuer

     

    Adicet Bio, Inc. (the “Issuer”)

     

    Item 1. (b) Address of Issuer’s Principal Executive Offices

     

    131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116

     

    Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:
       
      This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 444 Madison Avenue, Floor 35, New York, New York 10022.

     

    Item 2. (d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2. (e) CUSIP No.:

     

    007002108

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

     

    N/A

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    Item 4. Ownership

     

      As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:
       
      (a) Amount Beneficially Owned: 0
       
      (b) Percent of Class: 0%
       
      (c) Number of Shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote: 0
       
      (ii) Shared power to vote or to direct the vote: 0
       
      (iii) Sole power to dispose or to direct the disposition of: 0
       
      (iv) Shared power to dispose or to direct the disposition of: 0

     

    As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

     

      (a) Amount Beneficially Owned: 0
       
      (b) Percent of Class: 0%
       
      (c) Number of Shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote: 0
       
      (ii) Shared power to vote or to direct the vote: 0
       
      (iii) Sole power to dispose or to direct the disposition of: 0
       
      (iv) Shared power to dispose or to direct the disposition of: 0

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibit Index

     

      1. Joint Filing Agreement dated as of January 19, 2024, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on January 19, 2024).

     

     

     

     

    CUSIP No. 007002108 SCHEDULE 13G

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    Commodore Capital LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Managing Partner  
         
    Commodore Capital Master LP  
         
    By: /s/ Michael Kramarz  
    Michael Kramarz, Authorized Signatory  

     

     

    Get the next $ACET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACET

    DatePrice TargetRatingAnalyst
    9/30/2024$7.00Buy
    Guggenheim
    9/11/2024Buy → Neutral
    H.C. Wainwright
    6/27/2023Buy → Neutral
    Guggenheim
    6/27/2023Mkt Outperform → Mkt Perform
    JMP Securities
    6/1/2023$20.00 → $6.00Overweight → Neutral
    JP Morgan
    9/21/2022$23.00Overweight
    JP Morgan
    3/31/2022$28.00Outperform
    SMBC Nikko
    3/8/2022$30.00Buy
    Truist Securities
    More analyst ratings

    $ACET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended M

      5/6/25 4:01:00 PM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on April 30, 2025. Three individuals were hired by Adicet in April 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 206,800 shares of Adicet's common stock with an exercise price of $0.66 per share, the closing price of Adicet's common stock as reported by Nasdaq on April 30, 2025. One-fourth of the shares underlying each employee's option will vest on the one-year anniversary of each recipient's start date and thereafter the remaining

      4/30/25 4:47:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in New York. Details of the event are as follows: Date: Wednesday, May 7, 2025 Time: 1:30 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. i

      4/30/25 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 5:46:11 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 4:05:07 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

      SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

      11/14/24 4:00:05 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Leadership Updates

    Live Leadership Updates

    See more
    • Adicet Bio Appoints Michael Grissinger to the Board of Directors

      --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

      4/17/25 7:00:00 AM ET
      $ACET
      $APRE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

      Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c

      12/18/24 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo

      8/19/24 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    SEC Filings

    See more
    • SEC Form 10-Q filed by Adicet Bio Inc.

      10-Q - Adicet Bio, Inc. (0001720580) (Filer)

      5/6/25 4:07:37 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Adicet Bio, Inc. (0001720580) (Filer)

      5/6/25 4:04:06 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Adicet Bio Inc.

      DEFA14A - Adicet Bio, Inc. (0001720580) (Filer)

      4/29/25 4:09:13 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim resumed coverage on Adicet Bio with a new price target

      Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00

      9/30/24 8:04:57 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Adicet Bio from Buy to Neutral

      9/11/24 7:31:19 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio downgraded by Guggenheim

      Guggenheim downgraded Adicet Bio from Buy to Neutral

      6/27/23 10:07:31 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      1/26/24 7:14:22 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      1/26/24 7:13:05 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      10/2/23 8:16:14 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACET
    Financials

    Live finance-specific insights

    See more

    $ACET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

      Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda

      1/4/24 7:00:00 AM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

      Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To

      1/3/24 4:01:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

      ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved

      6/26/23 4:00:00 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Grissinger Michael

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      4/21/25 4:11:32 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Grissinger Michael

      3 - Adicet Bio, Inc. (0001720580) (Issuer)

      4/21/25 4:09:52 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Aftab Blake

      4 - Adicet Bio, Inc. (0001720580) (Issuer)

      2/4/25 4:42:39 PM ET
      $ACET
      Biotechnology: Pharmaceutical Preparations
      Health Care